95.23 - 97.14
55.47 - 103.81
1.63M / 1.80M (Avg.)
55.57 | 1.74
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
23.92%
Revenue growth under 50% of FSM's 87.57%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
42.28%
Gross profit growth under 50% of FSM's 205.23%. Michael Burry would be concerned about a severe competitive disadvantage.
51.76%
EBIT growth below 50% of FSM's 2308.53%. Michael Burry would suspect deeper competitive or cost structure issues.
51.76%
Operating income growth under 50% of FSM's 2308.53%. Michael Burry would be concerned about deeper cost or sales issues.
41.64%
Net income growth under 50% of FSM's 331.46%. Michael Burry would suspect the firm is falling well behind a key competitor.
37.50%
EPS growth under 50% of FSM's 312.12%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
37.50%
Diluted EPS growth under 50% of FSM's 312.12%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.11%
Share reduction more than 1.5x FSM's 7.49%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.43%
Diluted share reduction more than 1.5x FSM's 14.41%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-55.10%
Dividend reduction while FSM stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
50.27%
OCF growth under 50% of FSM's 1223.05%. Michael Burry might suspect questionable revenue recognition or rising costs.
49.75%
FCF growth under 50% of FSM's 148.32%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
153.70%
10Y revenue/share CAGR at 75-90% of FSM's 177.68%. Bill Ackman would press for new markets or product lines to narrow the gap.
80.52%
5Y revenue/share CAGR above 1.5x FSM's 49.90%. David Dodd would look for consistent product or market expansions fueling outperformance.
48.97%
3Y revenue/share CAGR above 1.5x FSM's 12.83%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
148.05%
10Y OCF/share CAGR under 50% of FSM's 367.95%. Michael Burry would worry about a persistent underperformance in cash creation.
106.30%
5Y OCF/share CAGR 1.25-1.5x FSM's 78.13%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
73.89%
3Y OCF/share CAGR at 75-90% of FSM's 92.88%. Bill Ackman would press for improvements in margin or overhead to catch up.
65.93%
Below 50% of FSM's 409.12%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
240.67%
5Y net income/share CAGR similar to FSM's 254.18%. Walter Schloss might see both on parallel mid-term trajectories.
121.59%
3Y net income/share CAGR above 1.5x FSM's 10.35%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
115.16%
10Y equity/share CAGR at 50-75% of FSM's 174.55%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
15.09%
Below 50% of FSM's 76.68%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.84%
3Y equity/share CAGR at 50-75% of FSM's 15.65%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
102.78%
Dividend/share CAGR of 102.78% while FSM is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
0.17%
3Y dividend/share CAGR of 0.17% while FSM is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
144.82%
Our AR growth while FSM is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
-0.70%
Negative asset growth while FSM invests at 2.96%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
2.37%
Positive BV/share change while FSM is negative. John Neff sees a clear edge over a competitor losing equity.
-23.76%
We’re deleveraging while FSM stands at 0.39%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-2.17%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.